[HTML][HTML] Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
X Fan, X Dai, Y Ling, L Wu, L Tang, C Peng… - The Lancet Infectious …, 2024 - thelancet.com
Summary Background Spread of SARS-CoV-2 led to a global pandemic, and there remains
unmet medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent …
unmet medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent …
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study.
X Fan, X Dai, Y Ling, L Wu, L Tang, C Peng… - The Lancet. Infectious …, 2023 - europepmc.org
Background Spread of SARS-CoV-2 led to a global pandemic, and there remains unmet
medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent that has …
medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent that has …
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
X Fan, X Dai, Y Ling, L Wu, L Tang… - The Lancet …, 2024 - pubmed.ncbi.nlm.nih.gov
Background Spread of SARS-CoV-2 led to a global pandemic, and there remains unmet
medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent that has …
medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent that has …
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
X Fan, X Dai, Y Ling, L Wu, L Tang, C Peng… - The Lancet Infectious …, 2024 - Elsevier
Summary Background Spread of SARS-CoV-2 led to a global pandemic, and there remains
unmet medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent …
unmet medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent …
[PDF][PDF] Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
X Fan, X Dai, Y Ling, L Wu, L Tang, C Peng, C Huang… - 2023 - colmedicosantafe2.org.ar
Summary Background Spread of SARS-CoV-2 led to a global pandemic, and there remains
unmet medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent …
unmet medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent …